Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending intravenous dose study of BAY 2253651 in healthy male volunteers
NL-OMON45895Not yet recruiting
- Sponsor
- Bayer
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) comparing BAY 2253651 with Placebo (2 arms). Primary endpoints: Pharmacokinetics of BAY 2253651 and Safety and tolerability. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
BAY2253651
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on NL-OMON45895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45895.